These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 10019-0553
Last updated: February 25, 2026
What is the drug associated with NDC 10019-0553?
NDC 10019-0553 corresponds to Busulfan injection, a chemotherapeutic agent used primarily for the conditioning treatment prior to hematopoietic stem cell transplantation in both malignant and non-malignant conditions.
Current Market Landscape
Market Size
Global Market Value (2022): Estimated at approximately USD 353 million.
Expected Compound Annual Growth Rate (CAGR): 3.2%, reaching USD 417 million by 2027.
Key Market Players
Company
Market Share
Product
Notes
Teva Pharmaceuticals
52%
Busulfan (generic version)
Dominates pricing and distribution
Sun Pharmaceutical
20%
Generic busulfan
Expanding market presence
Sandoz (Novartis)
15%
Generic formulations
Focus on hospitals
Other competitors
13%
Various generics
Fragmented landscape
Usage Trends
Increasing utilization in pre-transplant regimens.
Rising adoption in pediatric settings.
Growing use alongside targeted therapies for conditioning.
Price Dynamics
Drug Pricing Overview
Region
Average Price per Vial (USD)
Pricing Trends
United States
$80–$120
Slight decline over past five years due to generics.
European Union
€70–€100
Price stabilization post patent expiry.
Asia-Pacific
$50–$80
Lower prices, growing availability of generics.
Price Drivers
Generic Competition: Entry of multiple generics has compressed prices.
Regulatory Approvals: Faster approvals in emerging markets increase competition.
Supply Chain Factors: Manufacturing costs and supply constraints influence pricing.
Healthcare policy changes affecting drug reimbursement.
Technological improvements in manufacturing processes.
Regulatory and Reimbursement Landscape
FDA: Approved for use in conditioning therapy.
EMA: Approved with similar indications.
Reimbursement policies favor generics, especially in mature markets, pressuring prices downward.
Key Market Challenges
Limited differentiation in generic formulations.
Potential shortages due to supply chain issues.
Stringent regulatory hurdles in emerging markets.
Investment and R&D Opportunities
Development of new formulations (e.g., oral versions) could command premium pricing.
Comparative effectiveness studies may strengthen market position.
Expansion into unapproved or off-label indications could grow use.
Summary
NDC 10019-0553, identified as busulfan injection, operates within a mature yet competitive market. Generics dominate, driving prices downward and stabilizing at lower levels. The market is projected to see continued price erosion, with slight stabilization expected by 2027. Market growth is driven by increasing transplant procedures and expanding geographic penetration, especially in emerging markets.
Key Takeaways
Busulfan's market size is approximately USD 353 million globally (2022).
Competition from multiple generics has resulted in price declines, with current prices around USD 75–120 per vial in the U.S.
Price stabilization expected by 2027, with prices ranging from USD 58–100.
Growth prospects remain steady, driven by expanding transplant indications and new formulations.
Regulatory and reimbursement policies heavily influence market dynamics and pricing.
FAQs
When did generic busulfan enter the market?
Generic busulfan became widely available after patent expiry around 2010, leading to increased competition.
Are there any branded versions of busulfan?
No, busulfan is available predominantly as a generic drug; no currently marketed branded formulations exist.
What are the primary markets for busulfan?
The U.S., Europe, and emerging markets such as Asia-Pacific.
How might price trends be affected by new drug developments?
New formulations or biosimilars could either stabilize prices or further decrease them if they increase competition.
What regulatory hurdles exist for expanding busulfan's use?
Approval for new indications or formulations requires clinical trials and regulatory review, which can delay market entry and impact pricing strategies.
References
[1] Market Research Future. (2022). Busulfan Market Analysis.
[2] IQVIA. (2022). Global Oncology Drugs Market Data.
[3] U.S. Food and Drug Administration. (2022). Busulfan Drug Approval.
[4] European Medicines Agency. (2022). Busulfan Summary of Product Characteristics.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
